-

Wisp Hits 2 Million Patients and Sets Its Sights on Becoming Women’s Healthcare Home Base

New CEO Keira Krausz Takes the Helm as the Leading Women’s Telehealth Company
Expands Beyond Sexual and Reproductive Health into Fertility, Diagnostics, Menopause and More

NEW YORK--(BUSINESS WIRE)--Wisp, the largest women’s telehealth company in the U.S., today announced it has reached 2 million patients nationwide and appointed Keira Krausz as CEO, ushering in a new era of growth as the company expands beyond its roots in sexual and reproductive health to serve women across more stages of their lives.

Having established itself as the market leader in direct-to-consumer sexual and reproductive telehealth over the last eight years, Wisp continues to broaden its scope to address women’s health and wellness needs across every age and life stage. By scaling beyond acute reproductive treatments like STI and UTI care into long-term health and wellness – spanning hard-to-access prescription care, from menopause to skincare, as well as OTC products designed specifically for women’s biology, including vaginal probiotics, supplements and diagnostics – Wisp is transitioning from an episodic healthcare solution to a continuous health-span companion.

Wisp is building a trusted destination women can return to throughout their lives. Through 24/7 telehealth, at-home diagnostics, and personalized treatment plans, Wisp empowers women to navigate every transition – from their first birth control prescription to PMOS and midlife hormonal shifts tied to perimenopause – with comprehensive, frictionless, and stigma-free care.

“Two million patients is proof that women are looking for a fundamentally different healthcare experience – one that takes them seriously, fits into their lives, and doesn’t make them jump through hoops to get the care they need,” said Keira Krausz, CEO of Wisp. “Wisp has already changed the way millions of women access sexual and reproductive care. Now, we have an opportunity to bring that same experience to more of women’s health and build a platform that can be there for them not just for one moment, but for decades.”

A recognized Direct-To-Consumer expert with a track record of scaling companies in the women’s wellness space, Krausz takes the helm as Wisp moves from category leader to a broader women’s health platform. The company’s next phase will build on the accessibility and convenience that fueled its growth while expanding the range of care available to patients across sexual and reproductive health, diagnostics and at-home testing, perimenopause and menopause.

This expansion reflects a simple reality. Women’s health does not happen in isolated episodes. A patient seeking birth control or treatment for an infection today may be looking to build healthier routines tomorrow – from supplements and diagnostics to proactive treatments that support her health as her needs change. Yet healthcare has historically treated those needs as separate moments, often requiring women to start over with a new provider or system each time.

Wisp is building the opposite experience. Its growing platform is designed to meet women where they are and evolve alongside them, untangling the complexity that too often comes with accessing women’s healthcare. By making care, treatment, and testing more accessible from home across the country, Wisp is creating a more consistent experience regardless of where a patient lives.

With expert care across all 50 states, 2 million patients and counting, and an expanding portfolio of services, Wisp is positioning itself to become the most comprehensive destination for women’s healthcare in the U.S – built around the belief that women shouldn’t have to adapt to healthcare; healthcare should adapt to them.

About Wisp:

Wisp is the largest pure play women’s telehealth provider in the U.S., serving 2 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and at-home diagnostics. Recognized by Inc. as Best in Business 2025, TIME as Best Inventions of 2025, and Clio as Best Campaign in Health Equity of 2025. Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

Contacts

Media Contact:
SolComms
wisp@solcomms.co

Wisp


Release Versions

Contacts

Media Contact:
SolComms
wisp@solcomms.co

More News From Wisp

Wisp Collaborates with Mount Sinai to Expand Access to PrEP and HIV Prevention Across New York State

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women’s telehealth company in the U.S., today announced a collaboration with the Mount Sinai Health System, one of the largest academic medical systems in the New York metro area, to expand access to PrEP and HIV prevention to sexually active men, women and individuals across New York State. This collaboration is the first fully remote HIV prevention program launched by a New York City medical system — enhancing privacy, convenience, and ac...

ADDING MULTIMEDIA: Wisp and Visby Medical Partner to Provide Care with the First FDA-Authorized At-Home PCR STI Test

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women’s telehealth company in the U.S., today announced a partnership with Visby Medical, a leader in rapid at-home PCR diagnostics, in recognition of STI Awareness Week. Through the partnership, the two companies will expand access to Visby’s FDA-authorized at-home PCR STI test, with Wisp providing follow-up telehealth care for patients who test positive for chlamydia, gonorrhea, or trichomoniasis. According to the World Health Organizatio...

Wisp Debuts Women-Centric Longevity Suite Via New Healthy Aging Vertical

NEW YORK--(BUSINESS WIRE)--Wisp, the largest women’s telehealth company in the U.S., today announced its expansion into clinician-guided longevity care with the launch of its new Longevity and Healthy Aging category. The initial offering features five science-backed treatments - glutathione (nasal spray and injection), NAD+ (nasal spray and injection), and low-dose naltrexone (LDN) - which work to optimize your biology by fueling cellular energy and repair and recalibrate the immune system. The...
Back to Newsroom